含有酰胺的四氢苯并[4,5]噻吩并[2,3-d]嘧啶类化合物及其应用_2

文档序号:9342145阅读:来源:国知局
0 (s),13 09 (s),1193 (s),1138 (s),1070 (s),978 (s),774 (s) !1H-NMR(400MHz,CDCl3) : δ I. 40-1. 52 (m, 4Η, 2XCH2), I. 55-1. 60 (m, 2Η, CH2), I. 92-1. 97 (m, 4Η, 2 X CH2), 2. 89 (m, 2Η, CH2), 3. 14( m, 2Η, CH2), 3. 25 (t, 2Η, CH2-N), 3. 49 (t, 2Η, CH2-N), 3. 68 (s, 2Η, CH2-O), 7. 19 (dd, 1Η, Ar-H ,J1= 7. 6Hz, J2= I. 6Ηζ), 7. 27-7. 37(m, 2Η, Ar-H), 7. 64(dd, 1Η, Ar-H, J != 7. 6Hz, J 2 = L 6Ηζ), 8· 45 (s, 1Η, Ar-H) ;ESI-MS (m/z) : 440. 2 ([Μ+Η]+)。
[0036] 实施例3 :4-(2-二乙胺基甲酰基甲氧基苯硫基)-5, 6, 7, 8-四氢苯并[4, 5]噻吩 并[2, 3-d]嘧啶(化合物编号03)的制备
[0037] 参照实例1的方法,制得4-(2-二乙胺基甲酰基甲氧基苯硫基)-5, 6, 7, 8-四氢苯 并[4,5]噻吩并[2,3-d]嘧啶(化合物编号 03)0.4g,收率 72.2%。m.p· :117-119°C ;IR: (KBr,cm ) 3428 (m),2936 (s),1649 (s),1559 (s),1503 (s),1466 (s),1390 (s),1309 (s),1193 (s),1136 (s),1069 (s),974 (s),781 (s) !1H-匪R (400MHz,CDCl3) : δ 1.06-1. 10 (m,6H,2 X CH3 ),I. 91-1. 96 (m, 4H, 2 X CH2), 2. 88-2. 91 (m, 2H, CH2), 3. 12-3. 15 (m, 2H, CH2), 3. 18-3. 24 (m, 2 H, CH2-N), 3. 31-3. 36 (m, 2H, CH2-N), 3. 66 (s, 2H, CH2-O), 7. 19 (dd, 1H, Ar-H, J1= 8. 0Hz, J 2 = I. 6Hz), 7. 26-7. 30 (m, 1H, Ar-H), 7. 33-7. 37 (m, 1H, Ar-H), 7. 62 (dd, 1H, Ar-H, J1= 8. 0Hz, J 2 =I. 6Hz),8. 45 (s, 1H, Ar-H) ;ESI-MS (m/z) : 428. 2 ([M+H]+) 〇
[0038] 实施例4 :4-[2-(l-吡咯烷基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四氢苯并[4, 5] 噻吩并[2, 3-d]嘧啶(化合物编号04)的制备
[0039] 参照实例1的方法,制得4-[2-(1_吡咯烷基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四 氢苯并[4,5]噻吩并[2,3-d]嘧啶(化合物编号04)0.6g,收率80.9%。m.p· :146-147°C; IR: (KBr,cm 3 3432(m),2937 (s),2878(m),1646(s),1628(s),1557 (s),1506 (s),1471 ( s),1435 (s),1391 (s),1307 (s),1194 (s),1070 (s),977 (s),776 (s) !1H-匪R (400MHz,CD Cl3) : δ I. 77-1. 88 (m, 4H, 2XCH2), I. 91-1. 99 (m, 4H, 2 X CH2), 2. 89 (m, 2H, CH2), 3. 13 (m, 2H, CH2), 3. 32 (t, 2H, CH2-N), 3. 43 (t, 2H, CH2-N), 3. 60 (s, 2H, CH2-O), 7. 19 (dd, 1H, Ar-H ,J1= 7. 6Hz, J 2= I. 6Hz), 7. 27-7. 36 (m, 2H, Ar-H), 7. 66 (dd, 1H, Ar-H, J1=?. 6Hz, J 2 = I. 6Hz),8. 45 (s, 1H, Ar-H) ;ESI-MS (m/z) : 426. 0 ([M+H]+) 〇
[0040] 实施例5 :4-(2-苯胺基甲酰基甲氧基苯硫基)-5, 6, 7, 8-四氢苯并[4, 5]噻吩并 [2, 3-d]嘧啶(化合物编号05)的制备
[0041] 参照实例1的方法,制得4-(2-苯胺基甲酰基甲氧基苯硫基)-5, 6, 7, 8-四氢苯 并[4,5]噻吩并[2,3-d]嘧啶(化合物编号 05)0.3g,收率 57.9%。m.p· :187-189°C ;IR: (KBr,cm ) 3440 (m),3256 (d),2936 (d),1659 (s),1604 (s),1552 (s),1502 (s),1470 (s),1390 (8),1334(8),1306(8),1194(8),1067(8),974(8),767(111)^11-^^(4001^,0)(:13):5 1.92-1. 96 (m,4H,2 X CH2),2. 88-2. 90 (m,2H,CH2),3. 12-3. 14 (m,2H,CH2),3. 69 (s,2H,CH2-O),7. 08 -7. 12 (m, 1H, Ar-H), 7. 20 (dd, 1H, Ar-H, J1= 8. 0Hz, J 2= I. 2Hz), 7. 25-7. 38 (m, 6H, Ar-H), 7 ·46((Μ,1Η,Αγ-Η,Λ= 8.0Hz,J2= 1.2Hz),8.37(s,lH,Ar-H),8.53(s,lH,NH) ;ESI-MS(m/ z) : 448. I ([M+H]+)。
[0042] 实施例6 :4-[2-(4-氟苯胺基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四氢苯并[4, 5] 噻吩并[2, 3-d]嘧啶(化合物编号06)的制备
[0043] 参照实例1的方法,制得4-[2-(4_氟苯胺基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四 氢苯并[4,5]噻吩并[2,3-d]嘧啶(化合物编号06)0.2g,收率39.0%。m.p· :122-124°C; IR: (KBr,cm 3 3275 (m),2934 (s),1670 (s),1556 (s),1508 (s),1469 (s),1436 (s),1390 (s),I 305 (s),1197 (s),1067 (s),974 (s),835 (s),777 (s) !1H-NMR (400MHz,CDCl3) : δ I. 92-1. 96 (m ,4H, 2 X CH2), 2. 89 (m, 2H, CH2), 3. 12 (m, 2H, CH2), 3. 69 (s, 2H, CH2-O), 6. 96 (t, 2H, Ar-H), 7. 19 -7. 29 (m, 4H, Ar-H), 7. 34-7. 39 (m, 1H, Ar-H), 7. 45 (dd, 1H, Ar-H, J1= 8. 0Hz, J 2= I. 6Hz), 8 ? 32 (s, 1H, Ar-H),8. 56 (s, 1H, NH) ;ESI-MS (m/z) : 488. I ([M+H]+)。
[0044] 实施例7 :4-[3-(4-吗啉基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四氢苯并[4, 5]噻 吩并[2, 3-d]嘧啶(化合物编号07)的制备
[0045] 参照实例1的方法,制得4-[3-(4-吗啉基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四 氢苯并[4,5]噻吩并[2,3-d]嘧啶(化合物编号07)0.5g,收率87.5%。m.p· :117-119°C; IR: (KBr, cm ) 3444 (m),2929 (s),2857 (s),1679 (s),1659 (s),1591 (s),1496 (s),1468 (s),I 416 (s),1382 (s),1219 (s),1112 (s),1031 (s),831 (s),773 (s),684 (s) JH-NMRGOOMHz.CDC I3) : δ I. 92-1. 96 (m,4H,2 X CH2),2· 87-2. 89 (m,2H,CH2),3· 17-3. 19 (m,2H,CH2),3· 60-3. 68 (m, 8H, 2 X CH2-N, 2 X CH2-O), 4. 72 (s, 2H, CH2-O), 7. 06 (dd, 1H, Ar-H, J1= 7. 6Hz, J 2= 2. 8Hz ),7. 18 (t, 1H, Ar-H), 7. 23 (d, 1H, Ar-H, J = 8. 0Hz), 7. 39 (t, 1H, Ar-H), 8. 53 (s, 1H, Ar-H); ESI-MS (m/z) : 441. 9 ([M+H]+)。
[0046] 实施例8 :4-[3-(l-吡咯烷基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四氢苯并[4, 5] 噻吩并[2, 3-d]嘧啶(化合物编号08)的制备
[0047] 参照实例1的方法,制得4-[3-(1_吡咯烷基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四 氢苯并[4,5]噻吩并[2,3-d]嘧啶(化合物编号08)0.2g,收率30.9%。m.p· :103-105°C; IR: (KBr, cm 3 3422 (m),2932 (m),2867 (s),1678 (s),1574 (s),1493 (s),1407 (s),1352 (s),I 281 (s),1227 (s),1092 (s),829 (s),789 (s),689 (s) !1H-NMR (400MHz,CDCl3) : δ I. 83-2. 00 (m ,8Η,4 X CH2),2· 88 (m,2Η,CH2),3· 18 (m,2Η,CH2),3· 53 (t,4Η,CH2-N),4· 64 (s,2Η,CH2-O),7· 0 6 (dd, 1Η, Ar-H, J1= 8. 4Hz, J 2= 2. 0Hz), 7. 20 (t, 2Η, Ar-H), 7. 38 (t, 1Η, Ar-H), 8. 54 (s, 1Η, Ar-H) ;ESI-MS (m/z) :426. 1 ([Μ+Η]+)。
[0048] 实施例9 :4-(3-苯胺基甲酰基甲氧基苯硫基)-5, 6, 7, 8-四氢苯并[4, 5]噻吩并 [2, 3-d]嘧啶(化合物编号09)的制备
[0049] 参照实例1的方法,制得4-(3-苯胺基甲酰基甲氧基苯硫基)-5, 6, 7, 8-四氢苯并 [4,5]噻吩并[2,3-(1]嘧啶(化合物编号09)0.18,收率18.3%。111.?. :123-125°(:;11?:〇? r,cm 3 3375 (s),2929 (s),2855 (s),1685 (s),1603 (s),1544 (s),1493 (s),1444 (s),1407 (s) ,1319 (s),1226 (s),1129 (s),832 (s),764 (s),689 (s) !1H-NMR (400MHz,CDCl3) : δ I. 94-1. 96 (m,4H,2 X CH2),2· 88-2. 90 (m,2H,CH2),3· 17-3. 19 (m,2H,CH2),4· 65 (s,2H,CH2-O),7· 10 (dd, 1H, Ar-H, J1= 8. 4Hz, J 2= 2. 0Hz), 7. 16 (t, 1H, Ar-H), 7. 28 (t, 1H, Ar-H), 7. 36 (t, 3H, Ar-H) ,7. 44 (t, 1H, Ar-H), 7. 58 (d, 2H, J = 7. 6Hz), 8. 25 (s, 1H, NH), 8. 49 (s, 1H, Ar-H) ;ESI-MS (m/ z) : 448. 3 ([M+H]+) 〇
[0050] 实施例10 :4-[3-(4-氟苯胺基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四氢苯并[4, 5] 噻吩并[2, 3-d]嘧啶(化合物编号10)的制备
[0051] 参照实例1的方法,制得4-[3-(4_氟苯胺基)甲酰基甲氧基苯硫基]-5, 6, 7, 8-四 氢苯并[4, 5]噻吩并[2, 3-d]嘧啶(化合物编号10) 0· 6g,收率85. 1 %。m. P. : 151-152Γ; IR: (KBr, cm 3 3406 (s),2944 (m),1689 (s),1589
当前第2页1 2 3 4 
网友询问留言 已有0条留言
  • 还没有人留言评论。精彩留言会获得点赞!
1